University of Southern California, Los Angeles, California
Carlow University, Pittsburgh, Pennsylvania.
J Dr Nurs Pract. 2020 Mar 1;13(1):3-8. doi: 10.1891/2380-9418.JDNP-D-19-00033. Epub 2020 Jan 27.
In 2012 the Food and Drug Administration (FDA) approved Truvada (emtricitabine [FTC] 200 mg/tenofovir disoproxil fumarate [TDF] 300 mg) for preexposure prophylaxis (PrEP) against HIV. There was a substantial decline in new HIV diagnoses which has since stabilized.
The plateau is thought to be because preventative efforts are not reaching high-risk groups. About 1.2 million adults in the United States could benefit from PrEP but only 80,000 individuals are taking it. This article aims to increase provider awareness of PrEP so primary care providers feel confident discussing risk reduction options, initiating, and monitoring PrEP.
A case based approached is used to achieve the objective.
Target populations, baseline labs, follow up labs and monitoring parameters, and side effects of medication will be reviewed. Patient counseling with regards to dosing, administration, side effects and adverse events will be discussed.
HIV prevention is an integral public health goal. PrEP is a way to achiveeve continued reduction in HIV incidence. PCPs should be offering PrEP to at risk individuals.
Many nurse practitioners work as primary care providers, this article hopes to increase the confidence of PCPs in prescribing PrEP to those who would benefit from it.
2012 年，食品和药物管理局（FDA）批准了特鲁瓦达（恩曲他滨[FTC]200mg/替诺福韦二吡呋酯[TDF]300mg）用于 HIV 暴露前预防（PrEP）。新的 HIV 诊断病例数量大幅下降，此后趋于稳定。
人们认为这一稳定态势是因为预防工作没有覆盖到高风险群体。在美国，大约有 120 万成年人可以从 PrEP 中受益，但只有 8 万人在服用。本文旨在提高医务人员对 PrEP 的认识，使初级保健提供者有信心讨论减少风险的选择、启动和监测 PrEP。
采用基于案例的方法来实现这一目标。
将回顾目标人群、基线实验室检查、随访实验室检查和监测参数以及药物的副作用。将讨论与剂量、给药、副作用和不良事件有关的患者咨询。
艾滋病毒预防是公共卫生的一个重要目标。PrEP 是实现 HIV 发病率持续下降的一种方法。初级保健提供者应向高危人群提供 PrEP。
许多执业护士担任初级保健提供者，本文希望提高初级保健提供者为那些受益于 PrEP 的人开处方 PrEP 的信心。
